日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review)

乳腺癌中EGFR家族可溶性亚型:进展及临床意义(综述)

Yang, Peng; Jiang, Xinnong; He, Fangguo

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

小分子酪氨酸激酶抑制剂获批用于晚期肝细胞癌的全身治疗:最新进展和未来展望

Liu, Jianzhong; Xia, Shuai; Zhang, Baoyi; Mohammed, Dina Mostafa; Yang, Xiangliang; Zhu, Yanhong; Jiang, Xinnong

StraPep: a structure database of bioactive peptides

StraPep:生物活性肽的结构数据库

Wang, Jian; Yin, Tailang; Xiao, Xuwen; He, Dan; Xue, Zhidong; Jiang, Xinnong; Wang, Yan

Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases

酪氨酸激酶BMX磷酸化磷酸酪氨酸起始基序,从而激活多种受体酪氨酸激酶。

Chen, Sen; Jiang, Xinnong; Gewinner, Christina A; Asara, John M; Simon, Nicholas I; Cai, Changmeng; Cantley, Lewis C; Balk, Steven P

GABAB receptor complex as a potential target for tumor therapy

GABAB受体复合物作为肿瘤治疗的潜在靶点

Jiang, Xinnong; Su, Li; Zhang, Qian; He, Cong; Zhang, Zhongling; Yi, Ping; Liu, Jianfeng

Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.

在缺乏磷酸肌醇3-激酶同源物(PTEN)的前列腺癌细胞中,磷酸肌醇3-激酶通路激活与受体酪氨酸激酶无关,而是由p110β和p110δ催化亚基介导

Jiang Xinnong, Chen Sen, Asara John M, Balk Steven P

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

临床阶段的EGFR抑制剂不可逆地烷基化BMX激酶

Hur, Wooyoung; Velentza, Anastasia; Kim, Sungjoon; Flatauer, Laura; Jiang, Xinnong; Valente, David; Mason, Daniel E; Suzuki, Melissa; Larson, Brad; Zhang, Jianming; Zagorska, Anna; Didonato, Michael; Nagle, Advait; Warmuth, Markus; Balk, Steven P; Peters, Eric C; Gray, Nathanael S

Perlecan and tumor angiogenesis

蛋白聚糖和肿瘤血管生成

Jiang, Xinnong; Couchman, John R